Tevimbra (tislelizumab-jsgr)

LBL-007 plus tislelizumab and chemotherapy shows promising clinical benefits and manageable toxicity as first-line therapy for RM-NPC. Dual-positive LAG-3/PD-L1 expression was associated with improved outcomes, supporting further exploration of this biomarker-defined subpopulation in randomized trials.

Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients.

P2, N=30, Not yet recruiting, First Hospital of China Medical University

P2, N=192, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | N=80 --> 192 | Trial completion date: Jun 2027 --> Oct 2027 | Trial primary completion date: Jun 2027 --> Feb 2027

P1/2, N=60, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase classification: P1 --> P1/2 | N=40 --> 60 | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> May 2027

Subsequently, the patient was treated with an innovative regimen consisting of endoscopic intratumoral injections of Oncolytic adenovirus H101 in combination with the PD-1 inhibitor tislelizumab...The patient achieved nearly 4 months of progression-free survival and a substantial improvement in quality of life. This case highlights the potential of combining oncolytic virotherapy with PD-1 inhibition as a promising and novel personalized strategy for treating elderly patients with advanced gastrointestinal cancers who are unsuitable candidates for conventional therapies.

P2, N=95, Recruiting, University Hospital, Clermont-Ferrand | Not yet recruiting --> Recruiting

P2, N=60, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

At the last follow-up in August 2025, the patient had a progression-free survival (PFS) of 29.8 months, with no evidence of recurrence in the lung lesions. This case demonstrates the efficacy of a multimodal induction chemoimmunotherapy in achieving complete response and preserving organ function, thereby providing a promising therapeutic option for patients with synchronous lung and base-of-tongue SCC.

P2, N=30, Recruiting, Fondazione Ricerca Traslazionale

P1, N=7, Active, not recruiting, Shanghai Changzheng Hospital | Recruiting --> Active, not recruiting

P=N/A, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025